These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7823612)

  • 21. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials.
    Hemstreet GP; Rao J; Hurst RE; Bonner RB; Waliszewski P; Grossman HB; Liebert M; Bane BL
    J Cell Biochem Suppl; 1996; 25():197-204. PubMed ID: 9027619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Large bowel adenomas: markers of risk and endpoints.
    Baron JA
    J Cell Biochem Suppl; 1996; 25():142-8. PubMed ID: 9027611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methods and strategies in lung cancer control.
    Castonguay A
    Cancer Res; 1992 May; 52(9 Suppl):2641s-2651s. PubMed ID: 1562994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion.
    Samaha HS; Kelloff GJ; Steele V; Rao CV; Reddy BS
    Cancer Res; 1997 Apr; 57(7):1301-5. PubMed ID: 9102217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of proliferation indices as surrogate endpoint biomarkers.
    Alberts DS; Einspahr J; Aickin M; Hixson L; Earnest D; Roe D; Powell M
    J Cell Biochem Suppl; 1994; 19():76-83. PubMed ID: 7823609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
    Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
    Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
    Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
    Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin.
    Wali RK; Khare S; Tretiakova M; Cohen G; Nguyen L; Hart J; Wang J; Wen M; Ramaswamy A; Joseph L; Sitrin M; Brasitus T; Bissonnette M
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1653-62. PubMed ID: 12496057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cohorts with familial disposition for colon cancers in chemoprevention trials.
    Burt RW
    J Cell Biochem Suppl; 1996; 25():131-5. PubMed ID: 9027609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic considerations in the evaluation of chemopreventive data.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet RA; Greenwald P; Hawk ET; Fay JR; Sigman CC
    IARC Sci Publ; 1996; (139):203-19. PubMed ID: 8923032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant crypt foci in colon cancer epidemiology.
    Khare S; Chaudhary K; Bissonnette M; Carroll R
    Methods Mol Biol; 2009; 472():373-86. PubMed ID: 19107443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of aberrant crypt foci by chemopreventive agents.
    Olivo S; Wargovich MJ
    In Vivo; 1998; 12(2):159-66. PubMed ID: 9627797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
    Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
    Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of organoselenium compounds for potential chemopreventive properties in colon cancer.
    Reddy BS; Wynn TT; el-Bayoumy K; Upadhyaya P; Fiala E; Rao CV
    Anticancer Res; 1996; 16(3A):1123-7. PubMed ID: 8702223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
    Bostwick DG; Aquilina JW
    J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia.
    Boone CW; Kelloff GJ
    J Cell Biochem Suppl; 1994; 19():10-22. PubMed ID: 7823580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smokers and urinary genotoxins: implications for selection of cohorts and modulation of endpoints in chemoprevention trials.
    De Flora S; Camoirano A; Bagnasco M; Bennicelli C; van Zandwijk N; Wigbout G; Qian GS; Zhu YR; Kensler TW
    J Cell Biochem Suppl; 1996; 25():92-8. PubMed ID: 9027604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of chemoprevention in cancer control.
    Greenwald P; Kelloff GJ
    IARC Sci Publ; 1996; (139):13-22. PubMed ID: 8923016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.